哔哩哔哩(BILI.O)：此次发行包括腾讯认购2亿美元的哔哩哔哩可转换票据。

September 4 — Merck said China’s NMPA approved its PD‑1 inhibitor pembrolizumab for adults with resectable locally advanced head‑and‑neck squamous cell carcinoma whose tumors express PD‑L1 (combined positive score CPS ≥1) by a validated test. Approval covers single‑agent neoadjuvant use, postoperative adjuvant radiotherapy with or without cisplatin, and continued pembrolizumab monotherapy thereafter.

新西兰联储卡尔·汉森：未来的政策决策将取决于系列广泛经济数据的趋势。